In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer
- Cristina MüllerAffiliated withCenter for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer Institute
- , P. August SchubigerAffiliated withCenter for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer InstituteDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich
- , Roger SchibliAffiliated withCenter for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer InstituteDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
For the assessment of folate-based radiopharmaceuticals, human nasopharyngeal KB carcinoma cells are traditionally used although nasopharyngeal cancer is rare. On the other hand, the folate receptor (FR) is frequently overexpressed on diverse cancer types, the highest frequency (>90%) being on ovarian carcinomas. The goal of our study was the in vitro and in vivo assessment of different FR-positive human carcinoma cells. In addition, a murine sarcoma cell line was assessed as a pre-clinical alternative to human xenograft models.
FR-positive human nasopharyngeal, cervical, ovarian and colorectal cancer cell lines and the transgenic mouse sarcoma (24JK-FBP) cell line were targeted with a novel 99mTc-tricarbonyl folate derivative 2. Comparative in vitro cell binding studies were carried out under standardised folate-deficient conditions. In vivo studies were performed in nude mice and C6 black mice.
The in vitro cell experiments revealed only FR-specific binding (unspecific <0.02%), ranging from 3.5% to 52% of complex 2 owing to variable levels of FR expression of the cell lines. In vivo tumour uptake of radiotracer 2 varied less than in vitro. It ranged from 0.66±0.17% ID/g (LoVo) through 1.16±0.64% ID/g (IGROV-1) and 1.55±0.43% ID/g (24JK-FBP) to 2.33±0.36% ID/g (KB) 4 h p.i.
These pre-clinical studies indicate that in vitro data obtained in FR-positive cancer cells do not necessarily correspond with or predict in vivo radiofolate uptake in corresponding (xeno)grafts. In addition, the murine 24JK-FBP cell line proved to be a valuable pre-clinical alternative to human tumour models.
KeywordsFolates Tumour targeting Pre-clinical studies Diagnostic potential
- In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer
European Journal of Nuclear Medicine and Molecular Imaging
Volume 33, Issue 10 , pp 1162-1170
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Tumour targeting
- Pre-clinical studies
- Diagnostic potential
- Industry Sectors
- Author Affiliations
- 1. Center for Radiopharmaceutical Science ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
- 2. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, 8093, Zurich, Switzerland